The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.

Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC –– Company expects to present data ...

Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of CTD are very exciting and ...

RMB Latitudes Art Fair has announced that its third edition is set to take place in the Shepstone Gardens, johannesburg, from 23-25 May 2025.Presented by Latitudes Online in partnership with Rand ...

Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside” or the "Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ...

Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical ...

TURKU, FI / ACCESS Newswire / March 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potentialTURKU, FINLAND - Faron P ...